Sandoz Group Ltd · SIX:SDZ
Sandoz — Investor Day (2026)
10 slides from Sandoz's investor day presentation, Sep 7, 2026
Slide 1: A world-class commercial engine
A world -class commercial engine International Peter Stenico President International
Slide 2: Focused International platform backed by global pipeline
Market position Track record How to win Focused International platform backed by global pipeline Net sales International 2025 Leading position USD 3bn in biosimilars +19% 2 Generics Established commercial positioning 2025 biosimilar market size 3 Biosimilars 21% in core markets Large, attractive and
Slide 3: Strong growth expected in International markets, particularly in biosimilars
Market position Track record How to win Strong growth expected in International markets, particularly in biosimilars International biosimilar and generic markets 1 145 Market dynamics Gross sales, USD bn 17 By 2035E, International markets 91 71 will make up 65% of global 3 economic growth 2 2 128 88
Slide 4: Leadership position in biosimilars primes Sandoz for Bio100
Market position Track record How to win Leadership position in biosimilars primes Sandoz for Bio100 Net sales International #1 CAGR 2023 – 2025 USD bn 2.7 +8% 1 2.5 2.6 with 12 launched biosimilars 0.4 0.4 0.6 + 27 % Sandoz biosimilar share evolution 14% 6.3% 2.1 2.1 2.2 +4% 2023 2024 2025 2023 2024
Slide 5: Sandoz 360° strategy wins across market archetypes
Market position Track record How to win Sandoz 360 ° strategy wins across market archetypes Somatropin example Somatropin share evolution Sandoz 360 ° strategy Total International market1 Trusted partner in care Building preference through physician engagement, patient - and caregiver -centric progr
Slide 6: Targeted footprint and broad biosimilar portfolio drive platform
Market position Track record How to win Targeted footprint and broad biosimilar portfolio drive platform Sandoz in -market biosimilars 2 Footprint is aligned to Sandoz strong positioning Top Sandoz markets (direct 1) Total of >20 markets with direct presence 1 ~30 markets served via distributor mode
Slide 7: Leading position in significant biosimilar markets
Market position Track record How to win Leading position in significant biosimilar markets # 11 # 11,2 # 11 11 biosimilars 3 biosimilars 8 biosimilars Broadest biosimilar portfolio, Strong position with Commercial execution in line with EU/US HCP / hospital presence and portfolio expansion 60% first
Slide 8: Track record of broadening access for patients
Market position Track record How to win Track record of broadening access for patients Adalimumab example Estimated number of patients on treatment1 Productive development partnership (PDP) Thousands +45% Long -term public -private partnership in Granting access to patients unable to Brazil – the Mi
Slide 9: Scalable platform designed to support significant growth
Market position Track record How to win Scalable platform designed to support significant growth For top -11 biosimilar markets 1 Until year -end 2025… …By end of 2030 57 launches 2x 114 launches 20 years to get here 5 years to double impact Optimised International Tailored GTM model Strategic launc
Slide 10: Roadmap to setting industry standard in biosimilars, underpinned by clear strategic ambitions
Market position Track record How to win Roadmap to setting industry standard in biosimilars, underpinned by clear strategic ambitions Today By 2030 By 2035 Leading player Establishing biosimilar Extended market with resilience in a leadership leadership contested market Competitive and expanding Tri